Literature DB >> 2388874

Liver function assessment by drug metabolism.

L Barstow1, R E Small.   

Abstract

Liver function can be assessed by administering an exogenous substance to quantify changes in hepatic blood flow, uptake, biotransformation, and excretion. Characterization of drug half-life, clearance, and product formation rates are possible methods for measuring hepatic efficiency. Allopurinol and caffeine have been used to measure metabolite formation followed by renal elimination of both parent substance and metabolite. Sorbitol, a substance with high intrinsic clearance, can reflect liver blood flow, while trimethadione, a low-extraction drug, has been used to measure liver enzyme capacity. Metabolites from lidocaine, methacetin, and aminopyrine have been measured in serum, urine, and breath tests. Salivary clearance measurements of caffeine and antipyrine are reported as suitable for routine use. Genetic diversity of isoenzymes and the many metabolic processes used by hepatocytes make it extremely difficult to quantify functional changes with one substance. Combinations of model substrates have been suggested to assess the many hepatic processes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2388874

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  11 in total

Review 1.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

2.  Lidocaïne test for easier and less time consuming assessment of liver function in several hepatic injury models.

Authors:  Dorra Ben Said; Ridha Ben Ali; Henda Ferchichi; Issam Salouage; Lobna Ouanes; Emna Gaïes; Sameh Trabelsi; Emna Kooli; Nadia Kourda; Jaouida Abdelmoula; Mohamed Lakhal; Anis Klouz
Journal:  Hepatol Int       Date:  2011-03-23       Impact factor: 6.047

3.  Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration.

Authors:  A E Muñoz; C Miguez; M Rubio; M Bartellini; D Levi; A Podestá; V Niselman; R Terg
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

4.  Is there a sex difference in adult salivary clearance of caffeine (1,3,7-trimethylpurine-2,6-dione)?

Authors:  Basant K Puri; Christopher R Heard; Jean A Monro
Journal:  J Oral Biol Craniofac Res       Date:  2020-02-06

5.  Clinical significance of the trimethadione tolerance test in chronic hepatitis: a useful indicator of hepatic drug metabolizing capacity.

Authors:  M Abei; E Tanaka; N Tanaka; Y Matsuzaki; T Ikegami; A Ishikawa; T Osuga
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

6.  Lidocaine metabolite formation as a measure of perioperative liver function.

Authors:  K Shimanuki; I Sakurabayashi; M Miyata; H Kiyozaki; W Suzuki; A Kashii; N Seo
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

7.  Design considerations for tumour-targeted nanoparticles.

Authors:  Hak Soo Choi; Wenhao Liu; Fangbing Liu; Khaled Nasr; Preeti Misra; Moungi G Bawendi; John V Frangioni
Journal:  Nat Nanotechnol       Date:  2009-11-01       Impact factor: 39.213

8.  Effect of lidocaine on in vivo hepatic function.

Authors:  B Mets; R Hickman; U Neveling; M Emms; D O Chalton
Journal:  Dig Dis Sci       Date:  1993-12       Impact factor: 3.199

9.  Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial.

Authors:  Gadi Lalazar; Tomer Adar; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

10.  Tuned near infrared fluorescent hyaluronic acid conjugates for delivery to pancreatic cancer for intraoperative imaging.

Authors:  Bowen Qi; Ayrianne J Crawford; Nicholas E Wojtynek; Geoffrey A Talmon; Michael A Hollingsworth; Quan P Ly; Aaron M Mohs
Journal:  Theranostics       Date:  2020-02-10       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.